Your browser doesn't support javascript.
loading
Sertraline repositioning: an overview of its potential use as a chemotherapeutic agent after four decades of tumor reversal studies.
Baú-Carneiro, João Luiz; Akemi Guirao Sumida, Isabela; Gallon, Malu; Zaleski, Tânia; Boia-Ferreira, Marianna; Bridi Cavassin, Francelise.
Afiliação
  • Baú-Carneiro JL; Medical School Undergraduate Program, Faculdades Pequeno Príncipe (FPP), Curitiba, Brazil.
  • Akemi Guirao Sumida I; Medical School Undergraduate Program, Faculdades Pequeno Príncipe (FPP), Curitiba, Brazil.
  • Gallon M; Medical School Undergraduate Program, Faculdades Pequeno Príncipe (FPP), Curitiba, Brazil.
  • Zaleski T; Faculty of Medical Sciences, Faculdades Pequeno Príncipe (FPP), Curitiba, Brazil; Faculty of Biological Sciences, Universidade Estadual do Paraná (UNESPAR), Paranaguá, Brazil; Post Graduate Program of National Network's in Education, Universidade Federal do Paraná (UFPR), Curitiba, Brazil.
  • Boia-Ferreira M; Postdoctoral Program of Cellular and Molecular Biology, Universidade Federal do Paraná (UFPR), Curitiba, Brazil.
  • Bridi Cavassin F; Faculty of Medical Sciences, Faculdades Pequeno Príncipe (FPP), Curitiba, Brazil. Electronic address: francelise.cavassin@professor.fpp.edu.br.
Transl Oncol ; 16: 101303, 2022 Feb.
Article em En | MEDLINE | ID: mdl-34911014
Sertraline hydrochloride is a first-line antidepressant with potential antineoplastic properties because of its structural similarity with other drugs capable to inhibit the translation-controlled tumor protein (TCTP), a biomolecule involved in cell proliferation. Recent studies suggest it could be repositioned for cancer treatment. In this review, we systematically map the findings that repurpose sertraline as an antitumoral agent, including the mechanisms of action that support this hypotesis. From experimental in vivo and in vitro tumor models of thirteen different types of neoplasms, three mechanisms of action are proposed: apoptosis, autophagy, and drug synergism. The antidepressant is able to inhibit TCTP, modulate chemotherapeutical resistance and exhibit proper cytotoxicity, resulting in reduced cell counting (in vitro) and shrunken tumor masses (in vivo). A mathematical equation determined possible doses to be used in human beings, supporting that sertraline could be explored in clinical trials as a TCTP-inhibitor.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Transl Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Transl Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos